» Authors » Christoph Wenisch

Christoph Wenisch

Explore the profile of Christoph Wenisch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 84
Citations 724
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Oppenauer J, Clodi-Seitz T, Kornfehl A, Wenisch C, Eibensteiner F, Brock R, et al.
Sci Rep . 2025 Feb; 15(1):6137. PMID: 39979496
Hemophagocytic lymphohistiocytosis (HLH) is an excessive immune activation with cytokine storm und multi-organ dysfunction. It can occur secondarily, especially due to viral infections like COVID-19. Rapid treatment is crucial for...
2.
Jorda A, Ensle D, Eser H, Glotzl F, Riedl B, Szell M, et al.
Clin Microbiol Infect . 2024 Nov; 31(3):451-458. PMID: 39505067
Objectives: The real-world effectiveness of the oral antivirals nirmatrelvir-ritonavir and molnupiravir against the SARS-CoV-2 Omicron variant remains uncertain. We aimed to estimate their effectiveness in non-hospitalized adults with COVID-19. Methods:...
3.
Augustin M, Horn C, Ercanoglu M, Bondet V, de Silva U, Suarez I, et al.
Biomedicines . 2024 Oct; 12(10). PMID: 39457626
Background: Gastrointestinal mucosal damage due to human immunodeficiency virus (HIV) infection leads to microbial translocation and immune activation, contributing to the development of non-infectious comorbidities (NICM) in people living with...
4.
Balcar L, Schwarz M, Dorn L, Jachs M, Hartl L, Weseslindtner L, et al.
Liver Int . 2024 Oct; 44(12):3151-3163. PMID: 39351692
Background And Aims: Identification of people living with hepatitis C virus (HCV) via readily available laboratory records could be a key strategy for macro-elimination, aligning with the WHO elimination goal....
5.
Platzer M, Totschnig D, Karolyi M, Clodi-Seitz T, Wenisch C, Zoufaly A
Wien Klin Wochenschr . 2024 Jun; 136(15-16):458-464. PMID: 38884783
Background: Antiviral drugs have become crucial in managing COVID-19, reducing complications and mortality. Remdesivir has emerged as an effective therapeutic drug for hospitalized patients at risk of disease progression, especially...
6.
Clodi-Seitz T, Baumgartner S, Turner M, Mader T, Hind J, Wenisch C, et al.
Microorganisms . 2024 May; 12(5). PMID: 38792796
Background: Rapid diagnosis and identification of pathogens are pivotal for appropriate therapy of blood stream infections. The T2BacteriaPanel, a culture-independent assay for the detection of , , , , ,...
7.
Rathkolb V, Traugott M, Heinzel A, Poglitsch M, Aberle J, Eskandary F, et al.
iScience . 2023 Oct; 26(11):108146. PMID: 37867935
Despite the similar clinical outcomes after renin-angiotensin system (RAS) inhibitor (RASi) continuation or withdrawal in COVID-19, the effects on angiotensin-converting enzyme 2 (ACE2) and RAS metabolites remain unclear. In a...
8.
Augustin M, Stecher M, Wustenberg H, Di Cristanziano V, de Silva U, Picard L, et al.
Front Immunol . 2023 Oct; 14:1226622. PMID: 37781408
Background: While the short-term symptoms of post-COVID syndromes (PCS) are well-known, the long-term clinical characteristics, risk factors and outcomes of PCS remain unclear. Moreover, there is ongoing discussion about the...
9.
Schwarz C, Bauer D, Dorn L, Jachs M, Hartl L, Chromy D, et al.
Wien Klin Wochenschr . 2023 Sep; 136(9-10):278-288. PMID: 37773541
Background And Aims: Micro-elimination projects targeted to specific hepatitis C virus (HCV) risk populations have been successful. Systematic identification of persons with HCV viremia, regardless of risk group, based on...
10.
Seitz T, Bergmayr F, Kitzberger R, Holbik J, Grieb A, Hind J, et al.
Front Physiol . 2023 Aug; 14:1223347. PMID: 37614753
A severe course of COVID-19 is characterized by a hyperinflammatory state resulting in acute respiratory distress syndrome or even multi-organ failure along a derailed sympatho-vagal balance. In this prospective, randomized...